General Principles of Pharmacology

Correct Answer

B — Poor metabolizer

Rationale

The poor metabolizer phenotype describes individuals who carry two non-functional alleles of a drug-metabolizing enzyme gene and therefore have absent or negligible enzyme activity. Four metabolizer phenotypes are defined for enzymes like CYP2D6: poor metabolizers have no enzyme activity; intermediate metabolizers have reduced activity due to one functional and one non-functional allele; extensive metabolizers (the majority of the population) have normal activity; and ultrarapid metabolizers have increased activity, usually because they carry extra functional gene copies. For CYP2D6, the poor metabolizer phenotype has direct clinical consequences for drugs that depend on this enzyme for activation or elimination.

Correct Answer

D — Life-threatening bone marrow suppression due to accumulation of toxic thiopurine metabolites

Rationale

Thiopurine methyltransferase inactivates thiopurine drugs by methylation. In patients with absent enzyme activity, thiopurines are not inactivated by this pathway and instead accumulate and are converted to toxic thioguanine nucleotides at high concentrations. These metabolites cause severe, potentially fatal bone marrow suppression — pancytopenia requiring hospitalization. This is not a rare scenario: approximately 1 in 300 individuals is a thiopurine methyltransferase poor metabolizer. Testing thiopurine methyltransferase activity or genotype before starting any thiopurine drug is now standard of care and is explicitly recommended in drug labeling. Absent enzyme activity causes toxicity from accumulation, not therapeutic failure from inadequate drug levels.

Correct Answer

A — HLA-B*5701

Rationale

The HLA-B*5701 allele is tightly associated with abacavir hypersensitivity syndrome — a severe immune-mediated reaction characterized by fever, rash, gastrointestinal symptoms, and potentially life-threatening respiratory and cardiovascular compromise. The reaction occurs in approximately 5 to 8 percent of patients who carry this allele and is extremely rare in those who do not. Prospective genotyping before abacavir initiation and avoidance of the drug in carriers has effectively eliminated hypersensitivity reactions in screened populations. HLA-B*1502 is associated with severe cutaneous reactions to carbamazepine, particularly in patients of Southeast Asian ancestry. CYP2D6 and thiopurine methyltransferase testing are used for different drug-gene pairs.

Correct Answer

C — Excessive morphine generation from rapid codeine conversion, risking respiratory depression at standard doses

Rationale

Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to generate morphine, its active analgesic metabolite. In CYP2D6 ultrarapid metabolizers, this conversion is so rapid and extensive that a standard codeine dose generates morphine concentrations equivalent to a much larger morphine dose, potentially causing life-threatening respiratory depression. This is the mechanism responsible for reported deaths of nursing infants whose mothers were CYP2D6 ultrarapid metabolizers taking standard codeine doses, leading to FDA black box warnings and restrictions on codeine use in breastfeeding mothers and pediatric patients. The poor metabolizer phenotype produces the opposite outcome — absent conversion and no analgesia.

Correct Answer

B — Glomerular filtration rate has declined substantially with age, reducing the elimination of renally cleared drugs even in the absence of diagnosed kidney disease

Rationale

Glomerular filtration rate declines predictably with aging at approximately 1 percent per year after age 40, even in the absence of hypertension, diabetes, or other kidney disease. By age 75, a healthy individual may have lost 30 to 40 percent of peak renal function. This age-related decline in renal clearance prolongs the half-life of renally eliminated drugs and increases their steady-state plasma concentrations at standard doses. A serum creatinine level within the normal laboratory range can be misleading in older patients because reduced muscle mass produces less creatinine — the estimated glomerular filtration rate calculated from serum creatinine, age, and sex gives a more accurate picture. Renal function does not increase with age, and the decline is predictable enough to guide clinical dosing adjustments.

Correct Answer

D — Less than 10%

Rationale

A relative infant dose below 10 percent is the widely accepted threshold below which drug transfer through breast milk is generally considered unlikely to cause harm to a nursing infant, assuming the drug has no specific pediatric safety concerns. The relative infant dose accounts for both the concentration of drug in breast milk and the volume of milk consumed, expressed relative to the maternal dose adjusted for body weight. Drugs with relative infant doses well below 10 percent include many commonly used antibiotics, antihypertensives, and antidepressants. Drugs with relative infant doses above 10 percent, or drugs with known toxicity in neonates, require individual risk-benefit assessment. The LactMed database maintained by the National Institutes of Health provides current evidence-based guidance for specific drugs.

Correct Answer

A — Codeine requires CYP2D6-mediated conversion to morphine to produce analgesia; absent enzyme activity prevents this activation step

Rationale

Codeine itself has very weak affinity for opioid receptors. Its analgesic effect depends almost entirely on CYP2D6-mediated O-demethylation to morphine, the active opioid metabolite. In a CYP2D6 poor metabolizer, this conversion is absent — codeine is metabolized through other pathways that do not generate morphine, and the patient experiences no meaningful analgesia despite an apparently therapeutic codeine dose. This is the prototypical prodrug-pharmacogenomics interaction: the drug classification as a prodrug and the metabolizer phenotype together predict the clinical outcome. The solution for patients who require opioid analgesia is to use an opioid that does not require CYP2D6 activation, such as morphine itself.

Correct Answer

C — The mother is a CYP2D6 ultrarapid metabolizer who converts codeine to morphine far more rapidly than expected, producing high morphine concentrations in her milk

Rationale

CYP2D6 ultrarapid metabolizers convert codeine to morphine at a rate and completeness that far exceeds the population average. At a standard codeine dose, the mother generates morphine plasma concentrations equivalent to a much higher morphine dose, and these elevated concentrations transfer into breast milk. The nursing infant — who has immature drug metabolism — is then exposed to morphine concentrations sufficient to cause opioid toxicity. This clinical scenario, which led to infant deaths, prompted the FDA to add a black box warning to codeine contraindicating its use in breastfeeding mothers. It is a landmark example of how pharmacogenomic variation in a mother can indirectly harm an infant through breast milk.

Correct Answer

B — Clopidogrel requires CYP2C19-mediated activation to its active thiol metabolite; poor metabolizers cannot generate sufficient active drug to inhibit platelet aggregation

Rationale

Clopidogrel is a prodrug that undergoes two sequential CYP2C19-mediated oxidation steps to generate its active thiol metabolite, which irreversibly inhibits the platelet P2Y12 adenosine diphosphate receptor and blocks platelet aggregation. In CYP2C19 poor metabolizers, this activation is severely impaired — insufficient active metabolite is generated at standard doses, platelet inhibition is inadequate, and the risk of stent thrombosis is substantially increased. The FDA added a black box warning to clopidogrel noting that poor metabolizers may not receive full benefit. Alternative antiplatelet agents that do not require CYP2C19 activation, such as prasugrel or ticagrelor, are recommended for patients with documented CYP2C19 poor metabolizer status undergoing stent placement.

Correct Answer

D — Cytochrome P450 enzymes are immature at birth, leading to slower drug metabolism and risk of accumulation at standard doses

Rationale

Most cytochrome P450 enzymes are expressed at low levels at birth and reach adult activity levels over the first months to years of life, with different enzymes maturing at different rates. This immaturity means that neonates metabolize drugs more slowly than adults — including premature infants, whose enzyme maturation is even further delayed. Drug accumulation at standard doses is a genuine risk: the chloramphenicol gray baby syndrome, in which neonates develop cardiovascular collapse from chloramphenicol toxicity, is a historical example caused by immature glucuronosyltransferase-mediated conjugation and inadequate renal elimination. Hepatic function is present at birth but operating at reduced capacity. Neonates are not small adults pharmacokinetically, and dosing must account for developmental differences.

Correct Answer

A — Age-related reductions in hepatic and renal clearance prolong drug half-life, causing accumulation and higher plasma concentrations than expected in a younger adult

Rationale

Aging produces predictable pharmacokinetic changes that increase drug exposure for a given dose. Glomerular filtration rate falls approximately 1 percent per year after age 40, and hepatic mass and blood flow also decline, reducing both renal and hepatic drug clearance. For lipophilic benzodiazepines that are hepatically metabolized, slower clearance prolongs their half-lives so that drug accumulates with repeated dosing to concentrations higher than those achieved in a younger patient. In addition to these pharmacokinetic changes, older patients show increased pharmacodynamic sensitivity to central nervous system depressants — the same plasma concentration produces greater sedation, impaired balance, and increased fall risk. Both factors contribute to the disproportionate harm these drugs cause in older patients, which is why benzodiazepines appear on the Beers criteria list of drugs potentially inappropriate in older adults.

Correct Answer

C — Cirrhosis impairs first-pass hepatic extraction, allowing a much larger fraction of the oral dose to reach systemic circulation and opioid receptors

Rationale

In a patient with healthy liver function, approximately 50% of an oral morphine dose is extracted and metabolized by the liver on first pass before reaching the systemic circulation. In severe cirrhosis, reduced hepatic mass and portosystemic shunting dramatically impair this first-pass extraction — a much larger fraction of the absorbed dose bypasses hepatic metabolism and reaches the systemic circulation. The result is bioavailability far exceeding the usual 50%, producing plasma morphine concentrations substantially higher than expected from a standard oral dose. Morphine dosing in hepatic impairment must be reduced and initiated cautiously. Cirrhosis does not increase renal clearance; in fact, severe hepatic disease is often accompanied by reduced renal perfusion.

Correct Answer

B — Reduced albumin increases the unbound fraction of phenytoin, so the pharmacologically active free drug concentration is much higher than the total level suggests

Rationale

Only unbound (free) drug crosses cell membranes, reaches its pharmacological target, and produces effects. When albumin is reduced, a larger proportion of the total drug circulates as free drug. For a drug that is 90% protein-bound in a normal patient, only 10% is free and active. In a patient with severely reduced albumin, the unbound fraction may rise substantially — even if total plasma concentration appears within the reference range, free drug concentration can be two to three times higher than in a normal patient, causing toxicity. Standard therapeutic drug monitoring assays measure total drug. In hypoalbuminemic patients, free drug measurement is more clinically meaningful, or the lower end of the total concentration reference range must be targeted.

Correct Answer

D — Prolonged drug half-life and progressive accumulation to concentrations above those achieved in a patient with normal renal function

Rationale

When renal function is severely reduced, a drug that depends primarily on renal excretion is cleared much more slowly than in a patient with normal kidney function. The elimination half-life is prolonged in proportion to the reduction in clearance. With the same dose and dosing interval, less drug is eliminated between doses, and successive doses accumulate — steady-state concentrations exceed those in a normal patient and may enter the toxic range. The clinical response is to reduce the dose, extend the dosing interval, or both, based on the degree of renal impairment as estimated by glomerular filtration rate. Hepatic metabolism does not compensate for lost renal clearance of renally eliminated drugs. Compensatory tubular secretion does not occur in chronic kidney disease.

Correct Answer

C — Neonatal glucuronosyltransferase activity is immature, so chloramphenicol cannot be conjugated and accumulates to toxic concentrations

Rationale

Chloramphenicol is eliminated primarily by glucuronidation — a Phase Two conjugation reaction catalyzed by hepatic glucuronosyltransferase enzymes — followed by renal excretion of the conjugate. In neonates, glucuronosyltransferase activity is severely immature and does not reach adult levels until approximately three months of age. Without adequate glucuronidation, chloramphenicol accumulates in the neonate with repeated dosing, reaching concentrations that cause mitochondrial toxicity. The resulting syndrome — gray baby syndrome — is characterized by abdominal distension, vomiting, gray skin discoloration, circulatory collapse, and high mortality. This historical tragedy established the principle that neonates are pharmacokinetically distinct from adults and that drug dosing cannot simply be scaled by weight from adult values.

Correct Answer

A — Clopidogrel is a prodrug requiring CYP2C19 activation; absent enzyme activity prevents generation of the active thiol metabolite needed to inhibit platelet aggregation

Rationale

Clopidogrel must undergo CYP2C19-dependent oxidation to generate its active thiol metabolite, which irreversibly blocks the platelet P2Y12 adenosine diphosphate receptor and prevents platelet aggregation. In a CYP2C19 poor metabolizer, this hepatic activation step is absent or severely impaired. Despite adherence to the prescribed regimen, the patient's platelets remain largely uninhibited because insufficient active drug is generated. Stent thrombosis, which depends on platelet-mediated clot formation at the stent surface, occurs as a direct consequence of this pharmacogenomic drug failure. Patients with documented CYP2C19 poor metabolizer status undergoing coronary stent placement should receive an alternative antiplatelet agent — prasugrel or ticagrelor — that does not require CYP2C19 activation.

Correct Answer

D — Cirrhosis impairs hepatic first-pass extraction of propranolol, dramatically increasing its oral bioavailability and plasma concentration

Rationale

In healthy patients, propranolol's oral bioavailability is approximately 30% because the liver extracts and metabolizes roughly 70% of the absorbed dose on first pass through the portal circulation. In cirrhosis, reduced hepatic mass and portosystemic shunting bypass this extraction — a much larger fraction of the absorbed dose reaches the systemic circulation unchanged. Oral bioavailability rises well above the usual 30%, and plasma propranolol concentrations far exceed those expected from the dose. The result is exaggerated beta-adrenergic blockade: bradycardia, reduced cardiac output, and hypotension. Propranolol and other high-first-pass drugs must be initiated at substantially reduced doses in patients with significant hepatic impairment, with careful titration based on clinical response.

Correct Answer

B — Patients with absent thiopurine methyltransferase activity cannot inactivate thiopurine metabolites and are at risk for life-threatening bone marrow suppression at standard doses

Rationale

Thiopurine methyltransferase inactivates thiopurine drugs including azathioprine and 6-mercaptopurine through S-methylation. When enzyme activity is absent in a poor metabolizer, azathioprine is not inactivated by this pathway and is instead converted to toxic thioguanine nucleotides that accumulate and cause severe bone marrow suppression — pancytopenia with profound neutropenia, thrombocytopenia, and anemia — which can be fatal. Approximately 1 in 300 individuals carries two non-functional alleles and has absent enzyme activity. Pre-treatment testing allows the prescriber to avoid azathioprine entirely in poor metabolizers or use substantially reduced doses in intermediate metabolizers. This is a clinical example of pharmacogenomic testing preventing predictable, catastrophic harm. The HLA-B*5701 allele is relevant to abacavir hypersensitivity, not thiopurine toxicity.